利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.041 秒)

    Insulin resistance curative and method of screening the same
    4.
    发明申请
    Insulin resistance curative and method of screening the same 失效
    胰岛素抵抗治疗及筛选方法相同

    公开(公告)号：US20070059762A1

    公开(公告)日：2007-03-15

    申请号：US10558554

    申请日：2004-05-28

    申请人： Kazushi Araki ,  Jun Ohsumi ,  Makoto Yachi

    发明人： Kazushi Araki ,  Jun Ohsumi ,  Makoto Yachi

    IPC分类号： G01N33/53 ,  C07D413/02 ,  A61K31/4709

    CPC分类号： C12Q1/42 ,  G01N33/74

    摘要： The present invention provides a screening method for a compound which is highly safe and has a prophylactic or therapeutic effect on diabetes, and a highly safe pharmaceutical composition for the prophylaxis or treatment of diabetes. Specifically, a drug for the prophylaxis or treatment of diabetes, which contains, as an active ingredient, a compound having PPARγ activation activity and PTP inhibitory activity, and a method of screening for the drug are provided.

    摘要翻译： 本发明提供了高度安全且对糖尿病具有预防或治疗作用的化合物的筛选方法，以及用于预防或治疗糖尿病的高度安全的药物组合物。 具体地说，提供了含有作为活性成分的具有PPARγ活化活性和PTP抑制活性的化合物的糖尿病的预防或治疗药物以及该药物的筛选方法。

    METHOD FOR PRODUCING CERCOSPORAMIDE
    6.
    发明申请
    METHOD FOR PRODUCING CERCOSPORAMIDE 失效
    生产羧甲基纤维素的方法

    公开(公告)号：US20100152467A1

    公开(公告)日：2010-06-17

    申请号：US11997112

    申请日：2006-08-08

    申请人： Tsuyoshi Hosoya ,  Jun Ohsumi ,  Kiyoshi Hamano ,  Yasunori Ono ,  Masami Miura

    发明人： Tsuyoshi Hosoya ,  Jun Ohsumi ,  Kiyoshi Hamano ,  Yasunori Ono ,  Masami Miura

    IPC分类号： C07D307/77 ,  C12P17/04 ,  C12N1/14

    CPC分类号： C07D307/91 ,  C12P17/04 ,  C12R1/645

    摘要： The present invention provides a process for producing cercosporamide comprising culturing a fungus belonging to the genus Lachnum and/or fungus belonging to the genus Pseudaegerita and recovering cercosporamide from the culture thereof. In addition, the present invention provides cercosporamide acquired according to this production process. Further, the present invention provides novel microorganisms consisting of Lachnum fuscescens SANK 19096, Lachnum calycioides SANK 12497, Lachnum caesaliatum SANK 10906, and Pseudaegerita websteri SANK 11006.

    摘要翻译： 本发明提供了一种生产铈孢子酰胺的方法，其包括培养属于属于假单胞菌属的Lachnum属和/或真菌的真菌并从其培养物中回收孢子虫酰胺。 此外，本发明提供根据该制造方法获得的孢霉素。 此外，本发明提供了由Lachnum fuscescens SANK 19096，Lachnum calycioides SANK 12497，Lachnum caesaliatum SANK 10906和Pseudaegerita websterica SANK 11006组成的新型微生物。

    Insulin resistance curative and method of screening the same
    8.
    发明授权
    Insulin resistance curative and method of screening the same 失效
    胰岛素抵抗治疗及筛选方法相同

    公开(公告)号：US07718377B2

    公开(公告)日：2010-05-18

    申请号：US10558554

    申请日：2004-05-28

    申请人： Kazushi Araki ,  Jun Ohsumi ,  Makoto Yachi

    发明人： Kazushi Araki ,  Jun Ohsumi ,  Makoto Yachi

    IPC分类号： G01N33/53 ,  A61K31/47

    CPC分类号： C12Q1/42 ,  G01N33/74

    摘要： The present invention provides a screening method for a compound which is highly safe and has a prophylactic or therapeutic effect on diabetes, and a highly safe pharmaceutical composition for the prophylaxis or treatment of diabetes. Specifically, a drug for the prophylaxis or treatment of diabetes, which contains, as an active ingredient, a compound having PPARγ activation activity and PTP inhibitory activity, and a method of screening for the drug are provided.

    摘要翻译： 本发明提供了高度安全且对糖尿病具有预防或治疗作用的化合物的筛选方法，以及用于预防或治疗糖尿病的高度安全的药物组合物。 具体地说，提供了含有作为活性成分的具有PPARγ活化活性和PTP抑制活性的化合物的糖尿病的预防或治疗药物以及该药物的筛选方法。

    Pharmaceutical Composition for Enhancing Adiponectin Production
    9.
    发明申请
    Pharmaceutical Composition for Enhancing Adiponectin Production 审中-公开
    用于增强脂联素生产的药物组合物

    公开(公告)号：US20090088462A1

    公开(公告)日：2009-04-02

    申请号：US12086363

    申请日：2006-12-14

    申请人： Shoichi Kanda ,  Jun Ohsumi

    发明人： Shoichi Kanda ,  Jun Ohsumi

    IPC分类号： A61K31/427 ,  A61P5/00

    CPC分类号： A61K31/427

    摘要： Method for treatment of a human patient having hypoadiponectinemia. 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione or a pharmacologically salt thereof is administered in an amount effective to raise the level of adiponectine in said patient.

    摘要翻译： 治疗低脂联素血症的人类患者的方法。 5- [4-（6-甲氧基-1-甲基-1H-苯并咪唑-2-基甲氧基）苄基]噻唑烷-2,4-二酮或其药理学盐以有效提高所述脂联素水平的量 患者。

    Novel Cercosporamide Derivative
    10.
    发明申请
    Novel Cercosporamide Derivative 审中-公开
    新型Cercosporamide衍生物

    公开(公告)号：US20090036492A1

    公开(公告)日：2009-02-05

    申请号：US11990289

    申请日：2006-08-08

    申请人： Akihiro Furukawa ,  Jun Ohsumi ,  Tsuyoshi Arita ,  Takehiro Fukuzaki ,  Kazushi Araki ,  Makoto Mori ,  Takayuki Momose ,  Takeshi Honda ,  Masanori Kuroha ,  Ryo Okuyama ,  Susumu Satoh

    发明人： Akihiro Furukawa ,  Jun Ohsumi ,  Tsuyoshi Arita ,  Takehiro Fukuzaki ,  Kazushi Araki ,  Makoto Mori ,  Takayuki Momose ,  Takeshi Honda ,  Masanori Kuroha ,  Ryo Okuyama ,  Susumu Satoh

    IPC分类号： A61K31/443 ,  C07D307/91 ,  C07D405/12 ,  A61K31/343

    CPC分类号： C07D307/91 ,  C07D405/12 ,  C07D407/12

    摘要： The present invention relates to a novel cercosporamide derivative, a pharmacologically acceptable salt thereof or an ester thereof which has an excellent hypoglycemic effect and is useful as a therapeutic and/or prophylactic agent for diabetes.A cercosporamide derivative having the general formula (I): [wherein X represents an oxygen atom or the like, R1 represents a hydrogen atom or a C1-C6 alkyl group, R2 represents a hydrogen atom, a C1-C6 alkyl group or a C1-C6 halogenated alkyl group, R3 represents a hydrogen atom or a C1-C6 alkyl group, R4 represents a C6-C10 aryl group which may be substituted with one to five group(s) independently selected from Substituent Group a, or the like, n represents 1, 2 or 3, and Substituent Group a represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, a C2-C6 alkenyloxy group, a C2-C6 alkynyloxy group and the like], a pharmacologically acceptable salt thereof or an ester thereof.

    摘要翻译： 本发明涉及一种具有优异的降血糖作用，可用作糖尿病治疗和/或预防剂的新颖的孢子虫素衍生物，其药理学上可接受的盐或其酯。 具有通式（I）的孢孢酰胺衍生物：[其中X表示氧原子等，R 1表示氢原子或C 1 -C 6烷基，R 2表示氢原子，C 1 -C 6烷基或C 1 -C 6卤代烷基，R 3表示氢原子或C 1 -C 6烷基，R 4表示可以被一至五个独立地选自取代基组a的基团取代的C 6 -C 10芳基等， n表示1,2或3，取代基组a表示卤素原子，C1-C6烷基，C1-C6卤代烷基，C2-C6烯基，C2-C6炔基，C1-C6 烷氧基，C1-C6卤代烷氧基，C2-C6链烯氧基，C2-C6炔氧基等]，其药理学上可接受的盐或其酯。